DEA Telehealth Proposals for Controlled Substances

DEA Announces Proposed Rules for Permanent Telemedicine Flexibilities that would extend many adopted during the COVID-19 PHE with appropriate safeguards

Full Press Release

The first proposal “Expansion of induction of buprenorphine via telemedicine encounter” can be found here. The second proposed rule “Telemedicine Prescribing of Controlled Substances when the Practitioner and the Patient have not had a Prior In-person Medical Evaluation” can be found here.

NPRM comment period ends March 31, 2023 .

Additional resources for patients can be found here:

Additional resources for practitioners can be found here:

For more information on the DEA’s continued efforts to expand access to medications used in treatment for those suffering from opioid use disorder visit here.


CHIME Opioid Action Center

710 Avis Drive, Suite 200
Ann Arbor, MI 48108


Phone: 1.734.665.0000


Questions, comments? Submit your feedback below!

  • This field is for validation purposes and should be left unchanged.